|
Response
|
Visits
|
Robenacoxib (s.c. + oral)
|
Meloxicam s.c. + oral placebo
|
P
value (Mann–Whitney test)
|
Quotient robenacoxib:meloxicam (RMANCOVA)
|
P
value (RMANCOVA)
|
Transformation for RMANCOVA analysis
|
|---|
| | |
Mean (SD)
|
Mean (SD)
|
Mean
|
95% CI
| |
Exponential
|
P
value for normality (Shapiro-Wilks test)
|
|---|
|
Level of activity
|
D1-VF
|
0.62 (0.53)
|
0.64 (0.61)
|
0.96
|
0.972
|
0.658–1.373
|
0.87
|
0 (log)
|
<0.0001
|
|
Behaviour
|
D1-VF
|
0.29 (0.38)
|
0.31 (0.34)
|
0.57
|
1.285
|
0.731–2.240
|
0.34
|
−1 (reciprocal)
|
<0.0001
|
|
Appetite
|
D1-VF
|
0.38 (0.48)
|
0.37 (0.49)
|
0.69
|
1.006
|
0.551–1.672
|
0.98
|
−1 (reciprocal)
|
<0.0001
|
|
Interaction
|
D1-VF
|
0.23 (0.34)
|
0.26 (0.33)
|
0.70
|
1.306
|
0.696–2.452
|
0.36
|
−1 (reciprocal)
|
<0.0001
|
|
Global owner score
|
D1-VF
|
1.52 (1.42)
|
1.58 (1.45)
|
0.87
|
1.050
|
0.719–1.482
|
0.78
|
0 (log)
|
<0.0001
|
- CI: confidence interval; VF: final visit.
- Values are mean (SD) for each group and quotient values with 95% CI for the ratio robenacoxib/meloxicam. All assessments made by the owners are secondary end points. Assessments were made daily from the day after surgery (Day 1) to VF.
- Non-inferiority of robenacoxib versus meloxicam was concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.
- The level of activity, behaviour, appetite and interaction scores ranged from 0 to 3. The global owner score ranged from 0 to 12.
